Table 1 shows that interleukin-13 receptor alpha 2 (IL13-Rα2) (37), human epidermal growth factor receptor 2 (HER2) (36), and epidermal growth factor receptor variant III (EGFRvIII) (35) have been clinically verified as effective and safe targets of CAR T-cell therapy for GBM. This evidence concerns the gene ERBB2 and glioblastoma.